Affordable Access

Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690.

Authors
  • Kirkwood, John M1
  • Richards, Thomas
  • Zarour, Hassane M
  • Sosman, Jeffrey
  • Ernstoff, Marc
  • Whiteside, Theresa L
  • Ibrahim, Joseph
  • Blum, Ronald
  • Wieand, Samuel
  • Mascari, Ruth
  • 1 Department of Medicine, University of Pittsburgh, Pennsylvania, USA. [email protected]
Type
Published Article
Journal
Cancer
Publication Date
Sep 01, 2002
Volume
95
Issue
5
Pages
1101–1112
Identifiers
PMID: 12209697
Source
Medline
License
Unknown

Abstract

These data demonstrate changes in immunologic parameters associated with IFNalpha2b treatment and dosage that may account for some of the differences in the clinical efficacy of this modality. The current results also suggest the need for further study of newer molecular intermediates of IFNalpha2b and T-cell response to specific antigens of melanoma.

Report this publication

Statistics

Seen <100 times